A prospective study comparing short versus standard dual antiplatelet therapy in patients with acute myocardial infarction: design and rationale of the TARGET-FIRST trial.

Overview of attention for article published in EuroIntervention, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

news: 3 news outlets
twitter: 38 X users

facebook: 1 Facebook page

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

New England Journal of Medicine Publishes TARGET-FIRST: 1-Month DAPT with Firehawk™ Stents Lowers Bleeding Without Increasing Ischemic Events

MarketScreener, 01 Sep 2025

01 Sep 2025 TARGET-FIRST late-breaking at ESC 2025; NEJM publication. Shortening dual-antiplatelet therapy (DAPT) duration from…

What’s Going to Be Hot at ESC Congress 2025?

TCTMD, 25 Aug 2025

With 10 Hotline sessions, and 42 late-breaking science sessions, there is no shortage of new data for the practicing…

ESC 2025 : quelles sont les études attendues ?

Medscape, 19 Aug 2025

Plus de 40 études pivots seront dévoilées au cours des dix sessions Hot Line du Congrès de l’European Society of Cardiology (ESC…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.